Conflict of Interest Waiting to Happen? - NIH Nominee, Dr. Zerhouni
by a BuzzFlash Reader
I was reading this morning about Dr. Zerhouni's nomination to become the
new NIH chief and decided to do a bit of sleuthing. It becomes quite clear
early on that GWB and company are extremely interested in placing a Muslim
into a highly visible position to counter worldwide criticism of its policies
against people of Arab and Asian descent. Perhaps to mollify just a bit
the criticism of an attack on Sadam?
In addition, Johns Hopkins--Dr. Zerhouni's employer--is the largest recipient
of NIH grant money. Can he recuse himself from any future discussions
as to whether Johns Hopkins grant proposals are worthy of NIH funding?
In all likelihood, no. Why then would Dubya wish to place him into such
a compromising situation? Again, he needs a token Muslim.
With his and his Attorney General's blatant renunciation of a woman's
right to choose, why would Dubya nominate an Algerian who is [was] a very
strong advocate of embryonic stem cell research prior to the nomination?
How could a man with such convictions carry out his duties while hogtied
by this administration?
Following are just a few hits from my Google search. Very interesting.
Do read on.
Elias Zerhouni, MD, is the Chairman of the Department of Radiology and
the Donner Professor of Radiology at Johns Hopkins University School of
Medicine, where he is also the Executive Vice Dean for Clinical Services.
A graduate of the Medical School at the University of Algiers, he completed
his radiologic training at Hopkins and has been a leading developer of
MR imaging methods, especially MR angiography and intravascular MR imaging
$58.5 million gift will fund JHU science
Anonymous donation to create institute for stem cell research;
Treatments, patents beckon; Study could enable repair, replacement of
By Douglas Birch
The Johns Hopkins University's medical school will spend $58.5 million
- the second-largest gift in the university's history - to create an Institute
for Cell Engineering, where scientists will seek ways to use stem cells
to repair or replace diseased organs.
Dr. Elias Zerhouni, executive vice dean of the medical school, said the
institute's anonymous benefactor has made it possible for Hopkins to plunge
into one of the new century's most promising areas of medical research.
Elias A. Zerhouni, M.D.
410-614-6488; Fax: 410-955-0889
Gene Therapy: Treatment of cystic fibrosis; genetic therapies for prostate
cancer and other malignancies.
Genetic Diseases: Carnitine deficiency; hyperammonemia; urea cycle enzymopathies;
phenylketonuria; maple syrup urine disease; hereditary connective tissue
disorders; malformation syndromes; mucolipidoses and mucopolysaccharidoses;
neurological and mental retardation syndromes; gyrate atrophy; achondroplasia;
pseudoxanthoma elasticum; Marfan syndrome; immunologic and therapeutic
studies in patients with adrenoleukodystrophy; genetic studies of craniofacial
disorder (Treacher Collins syndrome).
Hopkins is the nation's largest recipient of biomedical research funding.
Last year, its labs received more than $255 million in grants from the
National Institutes of Health, with approximately $50 million going to
researchers in the eight basic science departments.
PRESIDENT EXPECTED TO TAP JHU OFFICIAL TO HEAD NIH
Reports the week of March 4 indicate that the President intends to nominate
Elias Zerhouni, executive vice dean of the Johns Hopkins University School
of Medicine, as director of the National Institutes of Health.
Zerhouni, a radiologist, is the school's second highest-ranking official.
He has been instrumental in developing the school's new Institute for
Cell Engineering, which is devoted partly to stem-cell research. News
sources indicate, however, that Zerhouni has given assurances that he
will adhere to the President's policy on stem-cell research, and to the
President's position on therapeutic cloning.